Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834852 | 0.98 | PDPK1 (0.40) | PDPK1GDAADORA3ADORA1XDH | |
| Thioguanine SCHEMBL9153902 | 0.82 | PDPK1 (0.63) | PDPK1GDAADORA1XDHMAP3K5 | |
| SCHEMBL5403767 | 0.79 | CDK2 (0.41) | PDPK1GDAADORA3ADORA1XDH | |
| SCHEMBL29366073 | 0.79 | PDPK1 (0.44) | PDPK1GDAADORA3ADORA1XDH | |
| SCHEMBL1275417 | 0.79 | PDPK1 (0.44) | PDPK1GDAADORA3ADORA1XDH | |
| SCHEMBL833645 | 0.76 | GDA (0.41) | PDPK1GDAADORA3ADORA1XDH | |
| SCHEMBL16146695 | 0.76 | PDPK1 (0.41) | PDPK1GDAADORA3ADORA1XDH | |
| SCHEMBL19780 | 0.76 | PDPK1 (0.66) | PDPK1GDAXDHMAP3K5CDK2 | |
| SCHEMBL16147074 | 0.76 | CDK2 (0.47) | PDPK1GDAADORA3ADORA1XDH | |
| SCHEMBL16146853 | 0.76 | PDPK1 (0.41) | PDPK1GDAADORA3ADORA1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| WO-2016027106-A1 | CELL ASSAY | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2016-02-25 | — | — | WO | disclosed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-20130005749-A1 | NOVEL FORMULATION AND TREATMENT METHODS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-01-03 | — | — | US | disclosed |
| EP-1825254-A4 | METHOD FOR OPTIMIZING THIOPURINE EFFICACY AND TOXICITY USING MASS SPECTROMETRY | PROMETHEUS LAB INC (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1825254-A2 | METHOD FOR OPTIMIZING THIOPURINE EFFICACY AND TOXICITY USING MASS SPECTROMETRY | Prometheus Laboratories, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060216726-A1 | Method for optimizing thiopurine efficacy and toxicity using mass spectrometry | PROMETHEUS LABORATORIES INC. (US) | 2006-09-28 | — | — | US | disclosed |
| WO-2006055527-A2 | METHOD FOR OPTIMIZING THIOPURINE EFFICACY AND TOXICITY USING MASS SPECTROMETRY | PROMETHEUS LABORATORIES INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-5164390-A | Cardiac disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| US-5021574-A | Cardiotonic agents, antiarrhythmia agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| US-4603219-A | 1,3-dibenzyloxy-2-acetoxymethoxypropane, intermediate for 9-(1,3-dihydroxy-2-propoxymethyl)guanine | SYNTEX (U.S.A.) INC. (US) | 1986-07-29 | — | — | US | disclosed |
| US-4507305-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1985-03-26 | — | — | US | disclosed |
| US-4423050-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4371613-A | TRANSARABINOSYLATION USING AN ENZYME FROM BACTERIA, AN ARABINOSE DONOR AND A PURINE SOURCE | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-02-01 | — | — | US | disclosed |
| US-4355032-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | PDPK1 281/4885GDA 1170/4885ADORA3 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.